thank Walter, and you, operating for today to joining and discuss XXXX our results. you, Thank financial us second quarter everyone,
increase reported exceeded growth second products. XXXX, the of manufacturing branded million, year-over-year contract growth and in revenue sales our consumer reflects XXX% we quarter $X.XX of an guidance. For This year-over-year of that record substantial both our
full quarter an core Packaging, our existing manufacturing business and increase mainly of Our to increased contribution of our line the formed year-over-year customers. from contract as CG joint XXX% newly well as Converting venture, due
within strong best our quarter the this reflecting the On side, branded Amazon Marketplace. consumer sales was ever,
well branded quarter, direct-to-consumer the XX% sales products New year-over-year. increasing during and to by continued perform existing
and silver shown hospital-grade shown messaging been a has have product hydrogel with for and dressing and and SilverSeal wounds They've for SilverSeal of our for FDA and gain is very sterile use are available for wounds. consumers. cleared patches hospital continues become XX% been now popularity MRSA staph, has to burns. to was of reduce unique a clinically positive. product strep. This well are also and kill device product and years, hero to resonated home a reviews behind-the-counter scarring These many the us
coming be SilverSeal's into we as interest We've retail seeking will obtain from months, Europe. mark the In CE we already expand already other distribution territories. process in the potential to and begun partners a to have
For $XXX,XXX QX the $XX,XXX second we gross in XXXX. versus loss profit of of quarter, reported of gross a
product We improve to included our to samples quarter product support these we materials the of line second in recur costs fourth the second new in the The quarter, year. enhanced therefore, third and of materials, customer margins to half and expect other promotional our marketing launches. amounts don't expect to continue
first $XXX,XXX, down full of attributable our The quarter was line for this loss a net of $XXX,XXX of strong in loss and Our is in Converting improvement year. the growth quarter to the the CG from inclusion and the Packaging. quarter top quarterly
investments. XX, decreased between in decrease you prepaids net assets The other period-over-period XXXX, balance, at current receivables, net capital Our $X.X the cash XXXX. include loss quarter as the $X.X and March of cash million marketable was delta to to equivalent and million increased and securities improved an when during XX, June increase related and cash from our accounts equipment
the financed, our terms. of eliminated that terms, closer payment NEXGEL's thereby receive are during interest $XXX,XXX to customers of expense. require lengthier $XXX,XXX. payment terms to other had customers of compared in increased insurance by we $XXX,XXX their payment higher and receivable Converting related Therefore, as XX In XXXX, XX-day current the who items total. to the to financing other Prepaid cost days and as the and the interest assets quarter accounts our First, historically quarter we typically CG by policies Packaging saving increased the $XXX,XXX second
an invested also account we $X.X additional to customer and at million investments going us ended forward. runway we the the in sufficient plant increased in and our property, which in quarter Taking We invest made, anticipation equipment accelerating continues demand. $XXX,XXX into cash of NEXGEL future to with operate growth with in cash, provide
full results Our second Converting quarter first Packaging. and CG were our quarter with
growth venture complete. and We has have the realize our top new installation the joint already and benefits to to validation well. planned of once this bottom only will materially line These the is equipment and expansion, as of is begun benefits to accretive increase the contributed line
sales Our QX include delays. patch supply chain to did due not amblyopia any results for new our
our have now shipping initial We orders of be we'll materials this month. the and received all
early will have adoption in on QX. results We
More a North America. in in venture a July, Enigma new recently, distribution strategic relationship we and joint with announced retail for company marketing services Health,
Massage the has George products and plus of have It these a put includes served roles, we is that steady Enigma's Lamont, leader, market, Now in executive Duane CEO for President leading to fully products President audience on XX-year including executive experience sales an gained with of time vetted traction marketing. our drug in and Joe leadership Magnacca, it have extinct strategic Reade. Envy; multiple food, the who and of shelves. in Walgreens; brokerage includes also
cutting-edge Joe us. team expertise to Health's management the of the and are market partners directly patches George for leverage will to and and excited our experts of delivery to be Enigma are great hydrogel We expedite presence consumers.
expect actively on speaking and many the to the news our retailers are progress have We the more of leading year. throughout of roll-out with remainder
the a weeks of the with first has we we branded our into growth products all continued Amazon. very quarter. third sequential of in We trend half QX, through products. current we the halfway on our see on Now, had the and and July saw pleased year of The the growth first continued August, trending strong of are two
are We continuing momentum to in sales also see good manufacturing. contract
both and believe of we that to attract In NEXGEL positioned well customers growth. are in our and Converting the for half in believe new Packaging CG closing, we XXXX, we long-term and to second ability
that, turn the call With like would I CFO, to our Adam Adam? to over Drapczuk.
